US FDA approves new therapy for myelodysplastic syndromes a rare form of blood cancers

The US FDA granted the approval of Tibsovo to Servier Pharmaceuticals LLC and RealTime IDH1 Assay to Abbott Laboratories. MDS are a rare form of blood cancers that can occur when the mutations in the bone marrow progenitor cells (cells that form blood) lead to insufficient numbers of healthy blood cells.